Holen Sie sich die Stockscreener-App
34.78
0.66%
-0.23
Handel nachbörslich:
34.78
Schlusskurs vom Vortag:
$35.01
Offen:
$35.22
24-Stunden-Volumen:
217.91K
Relative Volume:
0.89
Marktkapitalisierung:
$997.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.95M
KGV:
-23.41
EPS:
-1.4857
Netto-Cashflow:
$-50.43M
1W Leistung:
+12.56%
1M Leistung:
+8.96%
6M Leistung:
+54.37%
1J Leistung:
+0.00%
1-Tages-Spanne:
$34.03
$36.31
1-Wochen-Bereich:
$31.04
$36.60
52-Wochen-Spanne:
$13.36
$36.60
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
34.78 | 1.00B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
LB Pharmaceuticals Inc (LBRX) Balance Sheet - TradingKey
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LBRX|LB Pharmaceuticals Inc|Price:35.010|Chg%:+0.390 - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position - MarketBeat
Enterprise value to revenue forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock - Investing.com
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained - TipRanks
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on NA Companies: Exodus Movement, Inc. Class A (EXOD) and LB Pharmaceuticals, Inc. (LBRX) - The Globe and Mail
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo Finance Singapore
LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year HighTime to Buy? - MarketBeat
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline - TipRanks
LB Pharmaceuticals accelerates schizophrenia trial timeline By Investing.com - Investing.com South Africa
LB Pharmaceuticals accelerates schizophrenia trial timeline - Investing.com
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia - The Manila Times
LB Pharmaceuticals Expects Results From 460-Patient Trial in 1H 2027 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
JPMorgan Chase & Co. Increases Stake in LB Pharmaceuticals Inc. - GuruFocus
Jennison Associates LLC Sells 283,636 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
Enterprise value to EBITDA forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
LB PHARMACEUTICALS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $46 - Bitget
LBRX Initiated Coverage by BMO Capital -- Rated Outperform at $4 - GuruFocus
Price to book forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
BMO initiates LB Pharmaceuticals stock at Outperform on drug data By Investing.com - Investing.com South Africa
BMO initiates LB Pharmaceuticals stock at Outperform on drug data - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 2.68% as Shares Approach Key Resistance at $32.98Volatility Smile - dars.gov.et
Heather Turner: LB Pharma's Schizophrenia Drug Could Go from One Trial to Approval - finance.biggo.com
LB Pharmaceuticals Inc (LBRX) Holds Near $32 as Biotech Sector Shows Mixed SignalsADD Alert - dars.gov.et
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
LBRX Q1 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressFinancial Summary - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into FocusWyckoff Spring - DonanımHaber
LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule - Pluang
LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations - Quiver Quantitative
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
LB Pharmaceuticals Inc (LBRX) Edges Higher, Testing Key Resistance ZoneUp Down Ratio - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Gains 2.63% on Above-Average Volume, Tests Key Resistance at $36Call Wall - dars.gov.et
Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45 - Moomoo
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
LB Pharmaceuticals Initiated at Outperform by Wolfe Research - Moomoo
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageShort-Term Outlook - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):